Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05964829 |
Recruitment Status :
Recruiting
First Posted : July 28, 2023
Last Update Posted : February 7, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Chronic Progressive | Device: Cionic Neural Sleeve NS-100 Device: Actigraph accelerometer | Not Applicable |
The randomized within-participants crossover study aims to demonstrate the clinical impact of the Cionic Neural Sleeve for individuals diagnosed with MS.
Physical measurements, performance-based tests, and questionnaire responses will be recorded. These include physical activity recorded by an Actigraph; in-person tests measuring disability, spasticity and balance; and questionnaires gauging perceived walking ability, quality of life, and physical and psychological impact of MS.
All participants will be assigned a hip-worn Actigraph activity monitor, a Cionic Neural Sleeve on the most impacted leg, and prescribed a home-based intervention of 15 minutes of walking for 5 days a week for 12 weeks. The Actigraph will be worn for the duration of the 12-week walking intervention, while the Cionic Neural Sleeve will be worn for 6 weeks of the study.
Participants will be randomized to one of two groups: A or B. Group A will wear the Actigraph and receive stimulation assisted walking from the Neural Sleeve (intervention), while group B will only wear the Actigraph while walking. After 6 weeks, participants in each group will cross over to the other group.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 6 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | A Crossover Study Evaluating the Impact of the Cionic Neural Sleeve on Mobility, Disability, Fall Risk, and Physical Activity in Multiple Sclerosis |
Actual Study Start Date : | September 4, 2023 |
Estimated Primary Completion Date : | May 2024 |
Estimated Study Completion Date : | June 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Control
Participants will follow the walking program.
|
Device: Actigraph accelerometer
Physical activity will be recorded using an Actigraph accelerometer worn on the non-dominant hip. |
Experimental: Functional electrical stimulation
Participants will follow the walking program and receive stimulation assistance during the walking sessions.
|
Device: Cionic Neural Sleeve NS-100
The Cionic Neural Sleeve applies functional electrical stimulation as subjects walk to help contract appropriate muscles at appropriate times. The Cionic Neural Sleeve will be worn for 6 weeks. Device: Actigraph accelerometer Physical activity will be recorded using an Actigraph accelerometer worn on the non-dominant hip. |
- Change in Gait Speed [ Time Frame: Week 1, Week 6, Week 12 ]The Timed 25-Foot Walk Test (T25FWT) to record duration of time to walk a distance of 25 feet, measured in seconds. The score is the average of two successive trials.
- Change in Perceived Walking Ability [ Time Frame: Week 1, Week 6, Week 12 ]Multiple Sclerosis Walking Scale-12 (MSWS-12) to measure perceived impact of MS on walking ability, measured by score. Scores on the MSWS-12 range from 12-60 and transformed to a scale with a range from 0 to 100, with high scores indicative of a greater impact of MS on walking.
- Change in MS Disability [ Time Frame: Day 0, Week 6, Week 12 ]Expanded Disability Status Scale (EDSS), administered by a trained clinician, to quantify disability in MS and monitor changes in the level of disability over time. The EDSS scale ranges from 0 to 10, with high scores indicative of higher levels of disability.
- Change in Fall Risk [ Time Frame: Week 1, Week 6, Week 12 ]Berg Balance Scale (BBS) to assess balance in 14 tasks, measured by score. Scores of the BBS range from 0 to 56, with 0-20 being wheelchair bound, 21-40 being walking with assistance, and 41-56 classified as independent.
- Amount of Daily Walking/Activity Level [ Time Frame: Day 0, from enrollment to end of treatment at 12 weeks, post-intervention at Week 16 ]Collected by the usage log of the device(s), measured in steps per day
- Duration of Daily Walking/Activity Level [ Time Frame: Day 0, from enrollment to end of treatment at 12 weeks, post-intervention at Week 16 ]Collected by the usage log of the device(s), measured in duration of activity.
- Change in Health-Related Quality of Life [ Time Frame: Day 0, Week 6, Week 12 ]The Euroqol 5 Dimension 5 Level (EQ-5D-5L) questionnaire describes health profiles using different domains, measured by a 5-digit code. Single-digit numbers of the dimensions range from 1 to 5, with 1 indicative of no problem and 5 indicative of extreme problems in that domain.
- Change in Impact of MS [ Time Frame: Day 0, Week 6, Week 12 ]Multiple Sclerosis Impact Scale-29 (MSIS-29) questionnaire to measure the physical and psychological impact of MS, measured by score. Scores on the MSIS-29 are transformed into a score out of 100, with higher scores indicative of greater degree of disability.
- Change in Perceived Fatigue [ Time Frame: Day 0, Week 6, Week 12 ]Modified Fatigue Impact Scale (MFIS) survey to measure the effects of fatigue in physical, cognitive, and psychosocial functioning. MFIS score ranges from 0 to 84, with high scores indicative of a greater impact of fatigue on activities.
- Change in Spasticity [ Time Frame: Week 1, Week 6, Week 12 ]A trained clinician will administer the Modified Ashworth Scale (MAS) to assess for muscle tone and spasticity. Scores of the MAS range from 0 to 4, with high scores representative of increased muscle tone and spasticity.
- Change in Lower Limb Strength [ Time Frame: Week 1, Week 6, Week 12 ]Strength assessment of the ankle dorsiflexors, hamstrings, and quadriceps muscles using a handheld dynamometer in seated or laying in prone, measured in Newtons.
- Change in Ankle Plantarflexor Strength [ Time Frame: Week 1, Week 6, Week 12 ]Ankle plantarflexor strength will be measured by maximal repetitions of single leg heel raises.
- Change in Lower Limb Range of Motion [ Time Frame: Week 1, Week 6, Week 12 ]Range of motion of the ankle, knee, and hips will be assessed by a trained clinician using a handheld goniometer.
- Change in Walking Endurance [ Time Frame: Week 1, Week 6, Week 12 ]Measured via the 6-minute walk test, where subjects will walk as far as possible for 6 minutes, measured in meters.
- Change in Balance [ Time Frame: Week 1, Week 6, Week 12 ]Measured using force platform posturography in standing to quantify postural sway. There will be four 30-second trials with eyes open standing as still as possible.
- Change in Blood Lipids [ Time Frame: Week 1, Week 6, Week 12 ]Measured utilizing point of care analysis. The Cholestech LDX Analyzer provides accurate, actionable, and readily accessible results for point-of-care lipid profile and cholesterol testing, measured in milligrams per deciliter. Rapid, accurate results provide immediate awareness and identification of cardiovascular and diabetes health risks in only 5 minutes.
- Change in Blood Glucose [ Time Frame: Week 1, Week 6, Week 12 ]Measured utilizing point of care analysis. The Cholestech LDX Analyzer provides accurate, actionable, and readily accessible results for point-of-care glucose testing, measured in milligrams per deciliter. Rapid, accurate results provide immediate awareness and identification of cardiovascular and diabetes health risks in only 5 minutes.
- Change in Incidence of Falls [ Time Frame: From enrollment to end of treatment at 12 weeks, post-intervention at Week 16 ]Measured using a self-reported fall diary and a survey, the Hopkins Fall Grading Scale, a 4-point scale to grade the nature and severity of a fall. Higher grades represent increased severity and impact of injurious falls.
- Change in Medication(s) and Dosage [ Time Frame: Day 0, Week 1, Week 6, Week 12, post-intervention at Week 16 ]Measured by changes in dose intensities of prescribed medication(s).
- Change in Pain [ Time Frame: Week 1, Week 6, Week 12 ]Measured using the questionnaire, the Numeric Pain Rating Scale (NPRS), an 11-point numeric scale ranging from 0 to 10, with 0 being no pain and 10 being worst pain imaginable.
- Change in Self-Reported Physical Activity [ Time Frame: From enrollment to end of treatment at 12 weeks, post-intervention at Week 16 ]Subjects will record their weekly physical activity using the Godin-Leisure Time Exercise Questionnaire (GLTEQ), measured by score. Scores less than 14 units are interpreted as insufficiently active/sedentary, while scores between 14 and 23 are interpreted as moderately active, and scores greater than 24 units are interpreted as active.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 22 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Persons with relapsing-remitting or progressive forms of MS between the ages of 22 and 75
- Ability to ambulate at least 15 minutes throughout the day for five days per week, with or without assistive device
- Adequate cognitive and communicative function as assessed via Telephone Interview for Cognitive Status (TICS) to identify persons with dementia
- Able to tolerate the Neural Sleeve device for up to 8 hours per day
- T25FWT time between 8 and 45 seconds
- No recent change in medication or recent exacerbation of symptoms over the last 60 days
- Patient-determined Disease Steps score between 3 and 5 or EDSS score between 4 and 6.5
Exclusion Criteria:
- Lower motor neuron disease or injury (e.g. peripheral neuropathy) that may impair response to stimulation
- Absent sensation in the impacted or more impacted leg
- Inadequate response to stimulation, defined by inability to achieve muscle contraction or unable to tolerate stimulation
- Inability to ambulate with the sleeve in place of an ankle foot orthosis (AFO)/knee ankle foot orthosis (KAFO) if utilized
- History of falls greater than once a week
- No use of FES devices in the past year
- Demand-type cardiac pacemaker or defibrillator
- Malignant tumor in the impacted or more impacted leg
- Existing thrombosis in the impacted or more impacted leg
- Fracture or dislocation in the impacted or more impacted leg that could be adversely affected by motion from stimulation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05964829
Contact: Douglas A Wajda, PhD | 3308837149 | d.a.wajda@csuohio.edu | |
Contact: Rebecca Webster, PhD | 925-788-6649 | rebecca@cionic.com |
United States, Ohio | |
Cleveland State University | Recruiting |
Cleveland, Ohio, United States, 44115 | |
Contact: Douglas A Wajda |
Principal Investigator: | Douglas A Wajda, PhD | Cleveland State University |
Responsible Party: | Cionic, Inc. |
ClinicalTrials.gov Identifier: | NCT05964829 |
Other Study ID Numbers: |
CIONIC-06-001 |
First Posted: | July 28, 2023 Key Record Dates |
Last Update Posted: | February 7, 2024 |
Last Verified: | February 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Chronic Progressive Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System |
Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases Chronic Disease Disease Attributes |